DeepMed Research

Dimethyltryptamine

Generic Name: Dimethyltryptamine

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₆N_₂

CAS Number: 61-50-7

Unique Ingredient Identifier: WUB601BHAA

Background: An N-methylated indoleamine derivative, a serotonergic hallucinogen found in several plants, especially Prestonia amazonica (Apocynaceae) and in mammalian brain, blood, and urine. It apparently acts as an agonist at some types of serotonin receptors and an antagonist at others.

Indication: Some people use this compound as a psychedelic inducing agent.

Clinical Trials

Antidepressant Response of DMT Masked With Propofol

Not Applicable

Not yet recruiting

Conditions: Major Depressive Disorder
Psychedelic Experiences

Interventions: Drug: N,N-Dimethyltryptamine
Drug: Placebo
Procedure: no sedation
Procedure: Propofol

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 112

Registration Number: NCT06927076

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: LSD
Drug: Psilocybin
Drug: DMT
Drug: Placebo

First Posted Date: 2025-03-27

Last Posted Date: 2025-03-27

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 24

Registration Number: NCT06899334

Locations: 🇨🇭
University Hospital, Basel, Switzerland

Investigation of Psychedelic Effects in Psychoactive Substances

Phase 1

Recruiting

Conditions: Psychedelic Effects in Healthy Volunteers

Interventions: Drug: Placebo
Drug: Psilocybin
Drug: Ketamine
Drug: Dextromethorphan (DXM)
Drug: Dimethyltryptamine (DMT)
Drug: Methylenedioxymethamphetamine (MDMA)
Drug: Tetrahydrocannabinol (THC)

First Posted Date: 2025-01-14

Last Posted Date: 2025-02-06

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 50

Registration Number: NCT06772753

Locations: 🇺🇸
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States

Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

Phase 3

Not yet recruiting

Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)

Interventions: Drug: treatment withdrawal
Drug: Usual DMT continuation
Other: MRI
Behavioral: Quality of Life questionnaires
Other: Disability evaluation tests

First Posted Date: 2024-10-29

Last Posted Date: 2025-01-03

Lead Sponsor: University Hospital, Strasbourg, France

Target Recruit Count: 200

Registration Number: NCT06663189

Locations: 🇫🇷
CHU de Bordeaux-Hôpital Pellegrin, Bordeaux, France
🇫🇷
CHU de Caen-Hôpital Côte de Nacre, Caen, France
🇫🇷
CHU de Clermont-Ferrand-Hôpital Gabriel Montpied, Clermont Ferrand, France

and more 19 locations

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

Phase 2

Recruiting

Conditions: Treatment Resistant Depression

Interventions: Drug: VLS-01-203 BU
Drug: VLS-01-BU Placebo

First Posted Date: 2024-07-29

Last Posted Date: 2025-05-16

Lead Sponsor: atai Therapeutics, Inc.

Target Recruit Count: 142

Registration Number: NCT06524830

Locations: 🇨🇦
Centre for Neurology Studies, Surrey, British Columbia, Canada
🇺🇸
Woodland Research Northwest, Rogers, Arkansas, United States
🇺🇸
Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States

and more 8 locations

Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: 5 Methoxy N,N Dimethyltryptamine

First Posted Date: 2024-07-22

Last Posted Date: 2024-08-07

Lead Sponsor: GH Research Ireland Limited

Target Recruit Count: 52

Registration Number: NCT06511947

Locations: 🇬🇧
GH Research Clinical Trial Site, London, United Kingdom

Molecular Imaging Study of Harmine/DMT: a Basic Research Approach

Phase 1

Completed

Conditions: Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine

Interventions: Drug: N,N-dimethyltryptamine (DMT) + harmine
Drug: Placebo

First Posted Date: 2024-02-09

Last Posted Date: 2025-03-19

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 17

Registration Number: NCT06252506

Locations: 🇨🇭
Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland
🇨🇭
Psychiatric University Hospital Zurich, Zurich, Switzerland

Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression

Phase 2

Completed

Conditions: Depression, Unipolar
Depressive Disorder

Interventions: Drug: N,N-Dimethyltryptamine

First Posted Date: 2023-10-23

Last Posted Date: 2024-05-08

Lead Sponsor: Universidade Federal do Rio Grande do Norte

Target Recruit Count: 14

Registration Number: NCT06094907

Locations: 🇧🇷
Hospital Universitário Onofre Lopes, Natal, RN, Brazil

The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)

Phase 1

Not yet recruiting

Conditions: Alcohol Use Disorder (AUD)
Alcohol Use
Alcohol-Related Disorders

Interventions: Drug: 25 mg Diphenhydramine (5 min) + Normal Saline
Drug: 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion
Drug: 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion

First Posted Date: 2023-10-06

Last Posted Date: 2025-05-13

Lead Sponsor: Yale University

Target Recruit Count: 63

Registration Number: NCT06070649

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

Safety and Tolerability of DMT in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers
Safety Issues

Interventions: Drug: Placebo
Drug: N,N-Dimethyltryptamine

First Posted Date: 2023-06-13

Last Posted Date: 2023-10-11

Lead Sponsor: Universidade Federal do Rio Grande do Norte

Target Recruit Count: 25

Registration Number: NCT05901012

Locations: 🇧🇷
Hospital Universitário Onofre Lopes, Natal, RN, Brazil

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy